Project Details
Abstract
The human gut harbors > 100 trillion microbial cells, which influence the nutrition, metabolism,
physiology, and immune function of the host. Recent studies have highlighted the close relationship
between the kidney and the gastrointestinal tract frequently referred to as the kidney-gut axis-in patients
with chronic kidney disease (CKD).
Uremia increases intestinal permeability, both in uremic rats and in patients with CKD. The disruption
of colonic epithelial tight junction could subsequently lead to translocation of bacteria and endotoxin
across the intestinal wall. Gut microbiome dysbiosis is associated with bacterial translocation, thereby
contributing to microinflammation in patients with end stage renal disease. Endotoxin circulates in the
plasma of healthy humans at low concentrations (up to 200 pg/ml). Recent evidence indicates that
subclinical endotoxemia is a potential cause for inflammation in patients with CKD.
Calprotectin is a 24 kilodalton calcium and zinc-binding protein, released by leukocytes at the site of
inflammation. It can be detected in the feces where it remains stable for up to seven days. Increased
fecal calprotectin levels are found in different inflammatory conditions, mainly the inflammatory bowel
diseases. The relationship between fecal calprotectin and clinical outcome in peritoneal dialysis (PD)
patient has not been explored.
Protein fermentation by gut microbiota results in the generation of different metabolites, including
phenols and indoles. Concentrations of indoxyl sulfate and p-cresyl sulfate in the serum are negatively
correlated with the level of kidney function. An elevated level of indoxyl sulfate is associated with
vascular stiffness, aortic calcification, and higher cardiovascular mortality. Free serum levels of
p-cresol is associated with mortality in hemodialysis patients. Gut-derived uremic toxins contribute to
progression of CKD as well as cardiovascular disease.
Although the kidney-gut axis has been highlighted in patients with chronic kidney disease and end stage
renal disease, little is known in the contribution of gastrointestinal biomarkers to systemic inflammation
and clinical outcome of PD patients. The relationship among gastrointestinal biomarkers, intestinal
microbiota and clinical outcome in PD patient has not been explored. This study seeks to provide
insight into the following key questions: (1) To exam if the subclinical endotoxemia is a potential cause
for inflammation in PD patients and to explore the role of peritoneal endotoxin on patient outcome (2)
To explore if fecal calprotectin/cytokine could be a marker of intestinal inflammation in PD patients. (3)
To explore a potential immunoregulatory role of the intestinal microbiota in PD patients.
Project IDs
Project ID:PC10703-0219
External Project ID:MOST106-2314-B182-032
External Project ID:MOST106-2314-B182-032
Status | Finished |
---|---|
Effective start/end date | 01/08/17 → 31/07/18 |
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.